#obviousness

#obviousness

The Federal Circuit affirmed the invalidity of Purdue Pharma's OxyContin patents due to obviousness, impacting patent law standards.

The ruling highlights the importance of analyzing inherent properties and known problems in patent obviousness evaluations.

The Federal Circuit's first decision in 2025 addresses important issues of patent obviousness, providing clarity and direction for future cases.

The CAFC affirmed that the challenged Microsoft patent claims were obvious based on prior art, rejecting the inventor's arguments against the PTAB's findings.

The CAFC vacated the PTAB's decision, emphasizing the need for clear reasoning in obviousness determinations based on combined references.

CAFC denied Cisco and Hewlett-Packard's request to dismiss their appeal, emphasizing the importance of motivation in patent obviousness cases.

The Federal Circuit's ruling in Cytiva strengthens patent challengers' ability to invalidate patents claiming inherent properties in obvious inventions.

The Federal Circuit is hearing oral arguments in the design patent case of LKQ Corporation v. GM Global Technology Operations LLC.

LKQ argues that the Federal Circuit's obviousness standard makes it too difficult to reject or cancel design patent claims.

The PTAB reversed the eligibility rejection but affirmed the obviousness findings in Ex parte Annakov.